Every material Form 8-K Protara Therapeutics, Inc. has filed with the SEC since May 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Protara Therapeutics reported third quarter 2026 results, with a net loss of $21.7 million, or $0.35 per share, compared with a net loss of $13.3 million, or $0.31 per share, a year earlier. Research and development expenses rose to $16.8 million from $9.6 million, and the company said cash, cash equivalents and marketable debt securities of $143.1 million should fund operations into 2028.
Q3 2026 net loss of $21.7 million ($0.35 per share) vs. $13.3 million ($0.31 per share) in Q3 2025
R&D expenses rose to $16.8 million from $9.6 million, mainly from higher clinical trial costs of $4.4 million
Cash and marketable debt securities totaled $143.1 million as of September 30, 2026
On November 4, 2026, the company agreed to buy TARA-002 manufacturing-related assets from Novex Innovations for $8.75 million
Protara Therapeutics reported a second-quarter 2026 net loss of $21.7 million, or $0.36 per share, compared with a net loss of $15.0 million, or $0.35 per share, in the prior-year period. The filing reports no revenue line, and the higher loss reflects increased research and development spending, while the company says its cash position is expected to fund operations into 2028.
Net loss of $21.7 million ($0.36 per share) for the quarter ended June 30, 2026, versus $15.0 million ($0.35 per share) a year earlier.
Research and development expenses rose to $17.0 million from $10.8 million; general and administrative expenses rose to $6.4 million from $5.8 million.
Cash, cash equivalents and marketable debt securities totaled $161.9 million as of June 30, 2026, which the company expects to support operations into 2028.
Enrollment in the BCG-Unresponsive cohort of the ADVANCED-2 trial is expected to complete in the fourth quarter of 2026, and the ADVANCED-3 trial is being redesigned as an exploratory trial.
Protara Therapeutics said its Chief Medical Officer, Leonardo Viana Nicacio, M.D., resigned to explore other opportunities, effective June 26, 2026. His duties will be taken over by Carla Beckham, M.D., and will continue under the oversight of Jacqueline Zummo, Ph.D., the company's Chief Research & Development Officer.
Leonardo Viana Nicacio, M.D., Chief Medical Officer, resigned effective June 26, 2026, to explore other opportunities
Carla Beckham, M.D., Lead Medical Director and Head of Clinical Development, will assume Dr. Nicacio's duties
Jacqueline Zummo, Ph.D., Chief Research & Development Officer, will oversee the work
Protara Therapeutics reported a first-quarter 2026 net loss of $17.8 million, or $0.31 per share, up from $11.9 million, or $0.29 per share, a year earlier. The filing reports no revenue, and the loss widened as research and development and general and administrative expenses rose, but the company said its $177.4 million in cash and marketable securities should fund operations into 2028.
Net loss of $17.8 million, or $0.31 per share, for the quarter ended March 31, 2026, versus $11.9 million, or $0.29 per share, a year earlier
Research and development expenses rose to $13.6 million from $9.1 million, mainly due to ADVANCED-2 trial costs and ADVANCED-3 start-up costs
Cash, cash equivalents and marketable debt securities totaled $177.4 million as of March 31, 2026, expected to support operations into 2028
The company intends to submit a Biologics License Application for TARA-002 in lymphatic malformations in the second half of 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Protara Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →